Multiple reaction monitoring (MRM)‐profiling for biomarker discovery applied to human polycystic ovarian syndrome

• Published in: Rapid communications in mass spectrometry Vol. 31; no. 17; pp. 1462 - 1470
• Main Authors: Cordeiro, Fernanda B., Ferreira, Christina R., Sobreira, Tiago Jose P., Yannell, Karen E., Jarmusch, Alan K., Cedenho, Agnaldo P., Lo Turco, Edson G., Cooks, R. Graham
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 15.09.2017
• Subjects: Biomarkers; Biomarkers - analysis; Case-Control Studies; Classification; Diagnosis; Female; Follicular Fluid - chemistry; Functional groups; Glycolipids - analysis; Humans; Ions; Lipids; Monitoring; Patients; Phase transitions; Phosphatidylethanolamine; Polycystic ovary syndrome; Polycystic Ovary Syndrome - chemistry; Polycystic Ovary Syndrome - diagnosis; Principal Component Analysis; Principal components analysis; Quadrupoles; ROC Curve; Screening; Statistical analysis; Statistical methods; Tandem Mass Spectrometry - methods
• ISSN: 0951-4198; 1097-0231
• DOI: 10.1002/rcm.7927

Rationale We describe multiple reaction monitoring (MRM)‐profiling, which provides accelerated discovery of discriminating molecular features, and its application to human polycystic ovary syndrome (PCOS) diagnosis. The discovery phase of the MRM‐profiling seeks molecular features based on some prior knowledge of the chemical functional groups likely to be present in the sample. It does this through use of a limited number of pre‐chosen and chemically specific neutral loss and/or precursor ion MS/MS scans. The output of the discovery phase is a set of precursor/product transitions. In the screening phase these MRM transitions are used to interrogate multiple samples (hence the name MRM‐profiling). Methods MRM‐profiling was applied to follicular fluid samples of 22 controls and 29 clinically diagnosed PCOS patients. Representative samples were delivered by flow injection to a triple quadrupole mass spectrometer set to perform a number of pre‐chosen and chemically specific neutral loss and/or precursor ion MS/MS scans. The output of this discovery phase was a set of 1012 precursor/product transitions. In the screening phase each individual sample was interrogated for these MRM transitions. Principal component analysis (PCA) and receiver operating characteristic (ROC) curves were used for statistical analysis. Results To evaluate the method's performance, half the samples were used to build a classification model (testing set) and half were blinded (validation set). Twenty transitions were used for the classification of the blind samples, most of them (N = 19) showed lower abundances in the PCOS group and corresponded to phosphatidylethanolamine (PE) and phosphatidylserine (PS) lipids. Agreement of 73% with clinical diagnosis was found when classifying the 26 blind samples. Conclusions MRM‐profiling is a supervised method characterized by its simplicity, speed and the absence of chromatographic separation. It can be used to rapidly isolate discriminating molecules in healthy/disease conditions by tailored screening of signals associated with hundreds of molecules in complex samples.